Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors

BACKGROUND: Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 ((177)Lu)–Dotatate in patients with a...

詳細記述

保存先:
書誌詳細
出版年:N Engl J Med
主要な著者: Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P.L., Kulke, M.H., Jacene, H., Bushnell, D., O'Dorisio, T.M., Baum, R.P., Kulkarni, H.R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., Benson, A., Srirajaskanthan, R., Pavel, M., Mora, J., Berlin, J., Grande, E., Reed, N., Seregni, E., Öberg, K., Sierra, M. Lopera, Santoro, P., Thevenet, T., Erion, J.L., Ruszniewski, P., Kwekkeboom, D., Krenning, E.
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5895095/
https://ncbi.nlm.nih.gov/pubmed/28076709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1607427
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料